Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43903526" target="_blank" >RIV/00216208:11120/12:43903526 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/12:43903526

Výsledek na webu

<a href="http://dx.doi.org/10.1111/j.1469-0691.2012.03784.x" target="_blank" >http://dx.doi.org/10.1111/j.1469-0691.2012.03784.x</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/j.1469-0691.2012.03784.x" target="_blank" >10.1111/j.1469-0691.2012.03784.x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients

Popis výsledku v původním jazyce

A prospective, multicentre, phase IIIb study with an exploratory, open-label design was conducted to evaluate efficacy and safety of anidulafungin for the treatment of candidaemia/invasive candidiasis (C/IC) in specific ICU patient populations. . Patients received anidulafungin (200 mg on day 1, 100 mg/day thereafter) for 10-42 days, optionally followed by oral voriconazole/fluconazole. The primary efficacy endpoint was global (clinical and microbiological) response at the end of all therapy (EOT). Secondary endpoints included global response at the end of intravenous therapy (EOIVT) and at 2 and 6 weeks post-EOT, survival at day 90, and incidence of adverse events (AEs). The primary efficacy analysis was performed in the modified intent-to-treat (MITT) population, excluding unknown/missing responses. The safety and MITT populations consisted of 216 and 170 patients, respectively. The most common pathogens were Candida albicans (55.9%), C. glabrata (14.7%) and C. parapsilosis (10.0%).

Název v anglickém jazyce

Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients

Popis výsledku anglicky

A prospective, multicentre, phase IIIb study with an exploratory, open-label design was conducted to evaluate efficacy and safety of anidulafungin for the treatment of candidaemia/invasive candidiasis (C/IC) in specific ICU patient populations. . Patients received anidulafungin (200 mg on day 1, 100 mg/day thereafter) for 10-42 days, optionally followed by oral voriconazole/fluconazole. The primary efficacy endpoint was global (clinical and microbiological) response at the end of all therapy (EOT). Secondary endpoints included global response at the end of intravenous therapy (EOIVT) and at 2 and 6 weeks post-EOT, survival at day 90, and incidence of adverse events (AEs). The primary efficacy analysis was performed in the modified intent-to-treat (MITT) population, excluding unknown/missing responses. The safety and MITT populations consisted of 216 and 170 patients, respectively. The most common pathogens were Candida albicans (55.9%), C. glabrata (14.7%) and C. parapsilosis (10.0%).

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Microbiology and Infection

ISSN

1198-743X

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

680-687

Kód UT WoS článku

000305285200024

EID výsledku v databázi Scopus

—